Poly(ADP)ribosylation inhibitors (PARPis) are toxic to cancer cells with homologous
recombination (HR) deficiency but not to HR-proficient cells in the tumor microenvironment (TME), …

Testosterone therapy (TT) is administered to enhance masculinization in transgender individuals.
The long-term effect of exogenous testosterone on breast tissues remains unclear. Our …

Background: Manual qualitative and quantitative measures of terminal duct lobular unit (TDLU)
involution were previously reported to be inversely associated with breast cancer risk. …

We previously reported breast histopathologic features associated with testosterone therapy
in transmasculine chest-contouring surgical specimens. During that study, we observed a …

Background We investigated the associations of reproductive factors known to influence
breast cancer risk with the expression of breast stem cell markers CD44, CD24, and ALDH1A1 …

Digital pathology can efficiently assess immunohistochemistry (IHC) data on tissue microarrays
(TMAs). Yet, it remains important to evaluate the comparability of the data acquired by …

Objective: Determine the association between TT and breast tissue composition and breast
tissue density in trans masculine individuals (TMIs). Design: This is a cross-sectional study. …

Background: The relationships between PTEN loss and/or PIK3CA mutation and breast
cancer prognosis remain controversial. We aim to examine the associations in large …

Background: The majority of transmasculine individuals—assigned female at birth—pursue
gender-affirming testosterone therapy (TT) to treat their gender dysphoria. It remains …

Background: Transfeminine individuals—assigned male at birth—pursue gender-affirming
estrogen therapy to treat their gender dysphoria. When a transmasculine individual is …